Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ureteral Neoplasms: early-phase trial registry
1 of 3 indexed Ureteral Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Ureteral Neoplasms: 3 US clinical trials tracked, 1 recruiting.
Ureteral Neoplasms is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Astellas Pharma, running 1 of these trials.
Enrollment posture brief
Registry condition ureteral-neoplasms
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Ureteral Neoplasms lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ureteral Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ureteral Neoplasms is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company
NCT05614739
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Astellas Pharma Global Development
NCT03288545
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Astellas Pharma
NCT03219333
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ureteral Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ureteral Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ureteral Neoplasms page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Ureteral Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Astellas Pharma sponsors the most Ureteral Neoplasms trials on record, review their full trial history before evaluating a specific study. See Astellas Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ureteral Neoplasms condition card totals 3 registered trials; most-linked intervention enfortumab vedotin (EV); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.